Claims for Patent: 5,925,362

Summary for Patent: 5,925,362

Title:	Method to elicit an antitumor response with human prostate-specific antigen
Abstract:	Vaccines capable of eliciting an immune antitumor response for prostate tumors are disclosed. The active ingredient in such vaccines is selected from the group consisting of human PSA and expression system capable of generating in situ human PSA.
Inventor(s):	Spitler; Lynn E. (Tiburon, CA), Maida, III; Anthony E. (Danville, CA)
Assignee:	Jenner Technologies (San Ramon, CA)
Application Number:	08/288,057
Patent Claims:	1. A method to elicit an antitumor immune response to prostate tumors in a subject which comprises administering to said subject at least one active ingredient formulated for administration to said subject, wherein said active ingredient elicits an immune response to human prostate-specific antigen (PSA) and wherein said active ingredient is selected from the group consisting of human PSA; and an expression system capable of generating in situ said human PSA. 2. The method of claim 1 wherein said active ingredient is human PSA. 3. The method of claim 1 wherein said expression system comprises DNA comprising a nucleotide sequence encoding said human PSA. 4. The method of claim 3 wherein said expression system is on expression vector for said human PSA. 5. The method of claim 1 wherein said active ingredient is formulated to be encapsulated in a liposome or coupled to a liposome and wherein said liposomes optionally contain an adjuvant or are precipitated with alum. 6. The method of claim 1 which further includes at least one adjuvant capable of enhancing said antitumor immune response. 7. The method of claim 6 wherein said adjuvant is selected from the group consisting of Freund's complete adjuvant; alum; lipid A; monophosphoryl lipid A; Bacillus Calmette-Guerin (BCG) or other bacteria polysaccharides; saponins; detoxified endotoxin (DETOX); muramyl tripeptide or muramyl dipeptide or their derivatives; SAF1; lymphokines; cytokines; colony stimulating factors; nonionic block copolymers; and immune stimulating complexes (ISCOMS). 8. The method of claim 1 wherein said subject is afflicted with metastatic prostate cancer; and/or wherein said subject has been surgically treated to excise said tumor but is at risk for recurrence.

Details for Patent 5,925,362

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2016-07-20